Serum Ischemia-Modified Albumin, Fibrinogen, High Sensitivity C- Reactive Proteins in Type-2 Diabetes Mellitus without Hypertension and Diabetes Mellitus with Hypertension: A Case-Control Study

Publish Year: 1399
نوع سند: مقاله ژورنالی
زبان: English
View: 157

This Paper With 9 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_RBMB-9-2_015

تاریخ نمایه سازی: 22 دی 1399

Abstract:

Background: The objective of this study was to determine the levels of serum ischemia-modified albumin (IMA), fibrinogen (FIB) and high sensitivity C-reactive protein (hs-CRP) in type 2 diabetes mellitus (T2DM) patients with hypertension (HT) (DMT2HTN) and without HT (DMT2). Also, their association with certain biochemical and physical factors were studied to identify possible risk factors that lead to cardiovascular complications. Methods: Fasting blood samples were collected from 35 DMT2 or DMT2HTN patients each to analyze differences in serum and plasma levels of IMA, hs-CRP, FIB, total cholesterol (TC), high and low density lipoproteins (HDL and LDL), triglyceride (TG), hemoglobin A1c (HbA1C), glycated hemoglobin and creatinine. Results: In DMT2 and DMT2HTN patients, IMA, hs-CRP, FIB, TC, TG, HDL, LDL, glycated hemoglobin and creatinine levels, including body mass index (BMI) and waist-to-hip ratio (WHR), were significantly higher relative to healthy controls. In addition, the levels of IMA, hs-CRP and FIB levels showed a strong link to BMI, WHR, TC, TG, LDL and glycated hemoglobin. Lastly, both DMT2 and DMT2HTN patients demonstrated a significant reduction in HDL. Conclusions: DMT2 and DMT2HTN patients have a greater risk of developing cardiovascular related complications. This study suggests that quantifying hs-CRP, IMA and FIB levels can help diagnose the risk of developing complications during the early stages of metabolic and cardiovascular disease. Overall, the specific risk factors may be used for early identification of cardiovascular complications to decrease mortality and morbidity in T2DM patients.

Authors

Sushith Sushith

Department of Biochemistry, A. J. Institute of Medical Sciences and Research Centre, Mangaluru ۵۷۵۰۰۴, Karnataka, India

Herijenahalli Nagaraju Krishnamurthy

Department of Biochemistry, A. J. Institute of Medical Sciences and Research Centre, Mangaluru ۵۷۵۰۰۴, Karnataka, India

Shridhar Reshma

Department of Biochemistry, A. J. Institute of Medical Sciences and Research Centre, Mangaluru ۵۷۵۰۰۴, Karnataka, India

D'Sa Janice

Department of Biochemistry, A. J. Institute of Medical Sciences and Research Centre, Mangaluru ۵۷۵۰۰۴, Karnataka, India

Gopal Madan

Department of Biochemistry, A. J. Institute of Medical Sciences and Research Centre, Mangaluru ۵۷۵۰۰۴, Karnataka, India

Kumar Jeppu Ashok

Department of Biochemistry, A. J. Institute of Medical Sciences and Research Centre, Mangaluru ۵۷۵۰۰۴, Karnataka, India & International Medical School, Management and Science University, Shah Alam, Selangor ۴۰۱۰۰, Malaysia

Mangalore Balakrishna Prathima

Department of Biochemistry, A. J. Institute of Medical Sciences and Research Centre, Mangaluru ۵۷۵۰۰۴, Karnataka, India

Bhuvanesh Sukhlal Kalal

A. J. Research Centre, A. J. Institute of Medical Sciences and Research Centre, Mangaluru ۵۷۵۰۰۴, Karnataka, India & Ophthalmology, Visual & Anatomical Sciences, Wayne State University, Kresge Eye Institute, Detroit, Michigan ۴۸۲۰۱, United States of Ameri